UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT
In a report published Wednesday, Loewen Ondaatje McCutcheon downgraded its rating on BioMimetic Therapeutics (NASDAQ: BMTI) from Buy to Hold, but reiterated its $7.50 price target.
Loewen Ondaatje McCutcheon noted, “With BMTI trading within proximity of our 12-month price target of $7.50 per share, we have downgraded the shares to Hold (from Buy), reflecting a more balanced risk/reward profile.”
BioMimetic Therapeutics closed on Tuesday at $6.94.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.